JP2004508404A5 - - Google Patents

Download PDF

Info

Publication number
JP2004508404A5
JP2004508404A5 JP2002526380A JP2002526380A JP2004508404A5 JP 2004508404 A5 JP2004508404 A5 JP 2004508404A5 JP 2002526380 A JP2002526380 A JP 2002526380A JP 2002526380 A JP2002526380 A JP 2002526380A JP 2004508404 A5 JP2004508404 A5 JP 2004508404A5
Authority
JP
Japan
Prior art keywords
cancer
sodium channel
channel blocking
blocking compound
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2002526380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508404A (ja
Filing date
Publication date
Priority claimed from CNB001245171A external-priority patent/CN1284536C/zh
Application filed filed Critical
Publication of JP2004508404A publication Critical patent/JP2004508404A/ja
Publication of JP2004508404A5 publication Critical patent/JP2004508404A5/ja
Abandoned legal-status Critical Current

Links

JP2002526380A 2000-09-18 2001-09-11 鎮痛手法 Abandoned JP2004508404A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB001245171A CN1284536C (zh) 2000-09-18 2000-09-18 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
PCT/CN2001/001391 WO2002022129A1 (en) 2000-09-18 2001-09-11 A method of analgesia

Publications (2)

Publication Number Publication Date
JP2004508404A JP2004508404A (ja) 2004-03-18
JP2004508404A5 true JP2004508404A5 (enExample) 2008-11-06

Family

ID=4590472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002526380A Abandoned JP2004508404A (ja) 2000-09-18 2001-09-11 鎮痛手法

Country Status (26)

Country Link
US (1) US6407088B1 (enExample)
EP (3) EP1563839B1 (enExample)
JP (1) JP2004508404A (enExample)
KR (2) KR100891568B1 (enExample)
CN (1) CN1284536C (enExample)
AT (2) ATE447959T1 (enExample)
AU (1) AU2002213785A1 (enExample)
BG (1) BG107690A (enExample)
BR (1) BR0113961A (enExample)
CA (1) CA2421562C (enExample)
DE (1) DE60140466D1 (enExample)
EA (1) EA004870B1 (enExample)
EE (1) EE200300106A (enExample)
ES (1) ES2435463T3 (enExample)
HR (1) HRP20030202A2 (enExample)
HU (1) HUP0302677A3 (enExample)
IL (1) IL154342A0 (enExample)
IS (1) IS6719A (enExample)
MX (1) MXPA03002389A (enExample)
NO (1) NO323960B1 (enExample)
PL (1) PL360616A1 (enExample)
SK (1) SK3732003A3 (enExample)
UA (1) UA76960C2 (enExample)
WO (1) WO2002022129A1 (enExample)
YU (1) YU17103A (enExample)
ZA (1) ZA200301852B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047869A1 (en) 1997-04-22 1998-10-29 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
EA006739B1 (ru) * 2001-11-15 2006-04-28 Майкроу Элджи Корпорейшн Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
WO2004013637A1 (en) * 2002-08-01 2004-02-12 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
US20040209960A1 (en) * 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
CN101123967A (zh) * 2004-05-07 2008-02-13 菲特托克斯有限公司 藻毒素的经皮给药
WO2005110275A1 (en) * 2004-05-07 2005-11-24 Phytotox Limited Methods of treating wounds with gonyautoxins
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
CN100363006C (zh) * 2004-08-20 2008-01-23 厦门朝阳生物工程有限公司 一种戒毒制剂及其制备方法
EP1799219A1 (en) * 2004-09-21 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
WO2006032459A1 (en) * 2004-09-22 2006-03-30 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of peripheral-nervously derived neuropathic pain
EP1690541A1 (en) * 2005-02-11 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency
EP1714655A1 (en) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
TW200640463A (en) * 2005-02-11 2006-12-01 Esteve Labor Dr Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1702627A1 (en) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgesic combination of sodium channel blockers with opioid antagonists
WO2007025213A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the management of musculoskeletal pain
CA2619856A1 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1844781A1 (en) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of preterm labor
EP1844782A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel subunit Nav1.6
WO2007110220A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6
EP1844783A1 (en) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel - subunit Nav1.6
US9018222B2 (en) 2006-03-27 2015-04-28 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
CN100438873C (zh) * 2006-06-26 2008-12-03 黄致强 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用
EP1882692A1 (en) * 2006-07-28 2008-01-30 Wex Pharmaceuticals Inc. Dimethano-[1,3]dioxocino[6,5-D]pyrimidine-spiro derivatives of tetrodotoxin, process for their synthesis and uses thereof in the treatment of pain
AU2008275752A1 (en) * 2007-07-06 2009-01-15 Nuon Therapeutics, Inc. Treatment of neuropathic pain
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
US20120034296A1 (en) * 2009-04-08 2012-02-09 Massachusetts Institute Of Technology Prolonged duration local anesthesia with minimal toxicity
WO2011098539A1 (en) * 2010-02-10 2011-08-18 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives
WO2012075337A2 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
EA201591754A1 (ru) 2013-03-14 2016-01-29 Ридженерон Фармасьютикалз, Инк. Человеческие антитела к na1.7
RS58750B1 (sr) * 2013-03-15 2019-06-28 Childrens Medical Ct Corp Kombinovane formulacije neosaksitoksina za produženu lokalnu anesteziju
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药
US20240226105A1 (en) 2021-04-23 2024-07-11 Wex Pharmaceuticals Inc. Tetrodotoxin liquid formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US5846975A (en) * 1994-03-17 1998-12-08 Nanning Maple Leaf Pharmaceutical Co., Ltd. Use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
WO1998043619A2 (en) * 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Similar Documents

Publication Publication Date Title
CA2421562A1 (en) A method of producing analgesia using sodium channel blocking compounds such as tetrodotoxin, saxitoxin and derivatives thereof
JP2023179764A5 (enExample)
AU2016205138A1 (en) ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
CA2402169A1 (en) Formulation and method for treating neoplasms by inhalation
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
JP2005520778A5 (enExample)
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
JP2006514092A5 (enExample)
JP2020502206A (ja) Ｔａｓｋ−１およびｔａｓｋ−３チャネル阻害剤を含む医薬剤形、ならびに呼吸障害療法におけるその使用
JP2003515559A (ja) ゾルミトリプタン含有医薬製剤
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
CA2555457A1 (en) A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als
IL317168A (en) GCN2 modulator for cancer treatment
JPH07556B2 (ja) 間質性膀胱炎に対する治療用医薬組成物
US20240123168A1 (en) Product delivery devices and methods
JP2023109829A5 (enExample)
WO2004006929A1 (ja) 経鼻吸収用組成物
JP2021535163A5 (enExample)
CA2435921A1 (en) Method of cancer therapy
WO2014176417A1 (en) Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
WO2016014680A2 (en) Oral transmucosal compositions including aromatase inhibitors for low testoterone levels in men
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
KR930702985A (ko) 식도암의 치료